Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Lower urinary tract dysfunction is common among neurological patients. Traditionally, the basic method of diagnosis is a complex urodynamic study. In recent years, many studies have focused on the search for new non-invasive diagnostic modalities. In particular, neurotrophins are considered as potential biological markers of a neurogenic bladder. Aim. To estimate the sensitivity and specificity of the serum and urinary nerve growth factor (NGF) and brain neurotrophic factor (BDNF) in MS patients as markers of detrusor overactivity. Materials and methods. The study comprised 20 patients with multiple sclerosis, who complained of voiding problems. The control group consisted of 20 people without neurological diseases, lower urinary tract symptoms and detrusor overactivity estimated by filling cystometry. Apart from standard laboratory tests, diagnostic evaluation included a complex urodynamic study, ultrasound of the urinary tract, cystoscopy, testing serum and urinary NGF and BDNF using the enzyme immunoassay. The diagnostic significance of neurotrophins was evaluated using ROC analysis. Results. According to the ROC analysis, the diagnostic sensitivity and specificity of serum NGF as a marker of detrusor hyperactivity was 57% and 93%, respectively (for serum NGF ≥26 pg/ml). The quality of the test according to the expert scale of AUC values was «very good» (AUC=0.806). Detecting NGF in patients’ urine was less effective. The sensitivity and specificity were 52% and 40%, respectively (for NGF ≥6 pg/ml). The quality of the test according to the expert scale of AUC values was «average» (AUC=0.64). The serum BDNF demonstrated high sensitivity (90%) and low specificity (23%), AUC=0.56. The urinary BDNF was more informative, (AUC=0.65). The combination of all four markers provides a sensitivity of 85.7% and a specificity of 66.7% (AUC=0.824). Conclusions. Testing serum and urinary neurotrophins in patients with multiple sclerosis can be used to diagnose detrusor overactivity. The NGF is a highly specific biomarker, while the BDNF is highly sensitive. Combined testing for serum NGF and BDNF is most informative.

全文:

受限制的访问

作者简介

I. Bazhenov

UraI State Medical University of Minzdrav of Russia; SverdIovsk Regional Clinical Hospital No.1

Email: biv@okb1.ru
Dr.Med.Sci., Professor at the Department of Urology

E. Filippova

UraI State Medical University of Minzdrav of Russia; SverdIovsk Regional Clinical Hospital No.1

Email: filippova.cat@yandex.ru
Ph.D., Urologist at the SrCH №1, Teaching Assistant at the Department of Urology

V. Bazarnyi

UraI State Medical University of Minzdrav of Russia; SverdIovsk Regional Clinical Hospital No.1

Email: vlad-bazarny@yandex.ru
Dr.Med.Sci., Professor at the Department of Clinical Laboratory Diagnostics and Bacteriology

S. Sazonov

SverdIovsk Regional Clinical Hospital No.1

Email: prof-ssazonov@yandex.ru
Dr.Med.Sci., Professor, Head of the Department of Histology, Cytology and Embryology

L. Volkova

UraI State Medical University of Minzdrav of Russia; SverdIovsk Regional Clinical Hospital No.1

Email: vli@okb1.ru
Dr.Med.Sci., Professor, Head of the Department of Nervous Diseases, Neurosurgery and Medical Genetics

L. Zaitseva

UraI State Medical University of Minzdrav of Russia; SverdIovsk Regional Clinical Hospital No.1

Email: l.n.zaiceva@okb1.ru
Ph.D., Associate Professor at the Department of Pathological Anatomy

参考

  1. Гусев Е.И., Завалишин И.А., Бойко А.Н. Рассеянный склероз: Клиническое руководство. М.: Реал Тайм, 2011;528 с
  2. Шмитд Т.Е., Яхно Н.Н. Рассеянный склероз. М.: Медпресс, 2010; 267 с.
  3. Мазо Е.Б., Завалишин И.А., Кривобородов Г.Г., Шварц П.Г. Рассеянный склероз и нарушения мочеиспускания: клиника, диагностика, лечение. Неврологический журнал. 2002;(4):4-7
  4. Corcos J. A urological challenge: Voiding dysfunction in multiple sclerosis. Can Urol Assoc J. 2013;7(9-10 SuppI 4):181-182.
  5. Cho K.J., Kim J.C. Biomarkers for lower urinary tract dysfunction. Int J. Urol. 2013;20(1):13-20.
  6. Fry C.H., Sahai A., Vahabi B., Kanai A.J., Birder L.A. What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):602-605.
  7. Liu H.T., Lin H., Kuo H.C. Increased serum nerve growth factor levels in patients with overactive bIadder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn. 2011;30(8):1525-1529.
  8. Seth J.H., Sahai A., Khan M.S., van der Aa F., de Ridder D., Panicker J.N., Dasgupta P., Fowler C.J. Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int. 2013;111(3):372-380.
  9. Кривобородов Г.Г., Колесанова Е.Ф., Тур Е.И., Ефремов Н.С. Фактор роста нервов в моче у больных с идиопатической детрузорной гиперактивностью и гиперактивным мочевым пузырем без детрузорной гиперактивности. Урология. 2015;(3):19-22
  10. Kim S.R., Moon Y.J., Kim S.K., Bai S.W. NGF and HB-EGF: potential biomarkers that refIect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Med J. 2015;56(1):204-211.
  11. Ciftci S., Ozkurkcugil C., Yilmaz H., Ustuner M., Yavuz U., Yuksekkaya M., Cekmen M.B. Urinary nerve growth factor and a variable solifenacin dosage in patients with an overactive bladder. Int Urogynecol J. 2016;27(2):275- 280.
  12. Giannantoni A., Conte A., Farfariello V., Proietti S., Vianello A., Nardicchi V., Santoni G., Amantini C. OnabotuIinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. Pharmacol Res. 2013;68(1):118-124.
  13. Acosta C.M., Cortes C., MacPhee H., Namaka M.P. Exploring the role of nerve growth factor in muItipIe scIerosis: impIications in myeIin repair. CNS Neurol Disord Drug Targets. 2013;12(8):1242-1256.
  14. Vaidyanathan S., Krishnan K.R., Mansour P., Soni B.M., McDicken I. p75 nerve growth factor receptor in the vesicaI urotheIium of patients with neuropathic bIadder: an immunohistochemicaI study. SpinaI Cord. 1998;36(8):541-547.
  15. Laudiero L.B., Aloe L., Levi-Montalcini R., Buttinelli C., Schilter D., Gillessen S., Otten U. Multiple sclerosis patients express increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci Lett. 1992;147(1):9-12.
  16. Monteleone F., Nicoletti C.G., Stampanoni Bassi M., Iezzi E., Buttari F., Furlan R., Finardi A., Marfia G.A., Centonze D., Mori F. Nerve growth factor is eIevated in the CSF of patients with muItipIe scIerosis and central neuropathic pain. J. Neuroimmunol. 2017;pii: S0165-5728(17) 30179-0.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2018
##common.cookie##